AbCellera Prices Oversubscribed $200 Million Public Equity Offering to Fund Clinical Program ABCL635 (Vasomotor Symptoms) and Antibody Pipeline
AbCellera Biologics (NASDAQ: ABCL) announced Wednesday August 12, 2026 the pricing of an oversubscribed underwritten public offering of 17,435,897 common shares at $9.75 per share and pre-funded warrants to purchase up to 3,076,926 shares at $9.74999 per pre-funded warrant, for aggregate gross proceeds of approximately $200 million. Net proceeds of approximately $187 million are targeted to advance clinical development of lead program ABCL635 (an antibody-based candidate for vasomotor symptoms of menopause and related endocrine indications) plus additional immunology and oncology candidates. The offering closed August 14. AbCellera is a clinical-stage biotechnology company focused on discovering first-in-class antibody-based medicines in endocrinology, women's health, immunology, and oncology using its integrated antibody-discovery platform. Not a peptide company, but the offering is included here because AbCellera's platform overlaps with peptide-discovery approaches in the same discovery-to-clinical translation ecosystem, and the H2 2026 biotech financing window (which has already delivered Parabilis's $670M peptide IPO, Kardigan's $400M+ cardio IPO, and now AbCellera's $200M follow-on) reflects continued institutional appetite for platform-derived biologics.